Drug intelligence / Profile preview

MSB-2040

Development stage: Preclinical
Lead developer: MatriSys Bioscience
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Topical

Overview

MSB-2040 is a topical live biotherapeutic product (LBP) being developed by MatriSys Bioscience for the treatment of Netherton Syndrome. Netherton Syndrome is a rare and severe genetic skin disorder caused by mutations in the SPINK5 gene, which leads to a deficiency in the LEKTI protease inhibitor, resulting in chronic skin inflammation, barrier dysfunction, and increased susceptibility to infections. MSB-2040 utilizes beneficial commensal skin bacteria (bacteriotherapy) to restore the natural balance of the skin microbiome and potentially modulate the inflammatory environment associated with the disease. The drug is currently in preclinical development.

Beyond the preview

Go deeper on MSB-2040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSB-2040.

Explore the full profile